Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BDSX
HOLDBiodesix, Inc. · Healthcare · United States · $228M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Biodesix, Inc. is a diagnostics company that develops and commercializes rapid, blood-based tests for lung cancer and other pulmonary diseases. The company's competitive advantage lies in its proprietary multi-omics platform and artificial intelligence, which deliver actionable clinical results within 72 hours, bypassing the need for invasive tissue biopsies. Biodesix operates as a high-growth niche player in the precision oncology space, supported by expanding Medicare coverage and clinical adoption.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.2M | 49.1M | 71.3M | 88.5M | 32.3% | 96.1M | 111.0M | 132.8M | 22.5% |
| EPS | -11.62 | -5.95 | -6.60 | -4.67 | — | -3.91 | -2.96 | -1.77 | — |
| Shares | 10.4M | 10.4M | 7.3M | 8.3M | -20.3% | 10.4M | — | — | — |
| Debt | 31.9M | 60.7M | 62.0M | 72.9M | 31.8% | 73.6M | — | — | — |
| Equity | 20.6M | 4.6M | 20.9M | -2.5M | 0.7% | — | — | — | — |
| Op CF | -45.0M | -22.9M | -48.6M | -23.3M | — | -24.8M | — | — | — |
| Inv CF | -3.5M | -23.1M | -3.4M | -0.4M | — | — | — | — | — |
| Fin CF | 58.9M | 29.1M | 52.0M | 16.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BDSX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BDSX | Biodesix, Inc.(you) | $228M | 38 | HOLD |
| MYGN | Myriad Genetics, Inc. | $530M | 35 | SELL |
| FLGT | Fulgent Genetics, Inc. | $559M | 27 | SELL |
| OPK | OPKO Health, Inc. | $921M | 35 | HOLD |
| XGN | Exagen Inc. | $113M | 17 | STRONG SELL |
| IMDX | Insight Molecular Diagnostics Inc. | $153M | 7 | STRONG SELL |
| CSTL | Castle Biosciences, Inc. | $749M | 19 | STRONG SELL |
| NEO | NeoGenomics, Inc. | $1.8B | 45 | HOLD |
| PSNL | Personalis, Inc. | $1.3B | 24 | SELL |
| 950130.KQ | Access Bio, Inc. | $60M | 9 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%